GLP-1 Drugs and Menopause: What We Know About Ozempic, Wegovy, and HRT

If you're a woman in perimenopause or menopause and you've also been prescribed a GLP-1 receptor agonist like Ozempic, Wegovy, or Mounjaro, you're not alone. Millions of women are now navigating both of these treatments simultaneously. And yet, when you ask your doctor how these drugs interact with hormone replacement therapy, you're likely to get a shrug.

That's not because the question isn't important. It's because the research is still catching up to what's happening in real life. But there is emerging evidence, and it matters. Here's what we know so far, what we don't, and what you should be discussing with your provider.

The overlap is massive — and underresearched

Roughly 1.7 million women in the U.S. are currently prescribed GLP-1 medications for weight management or type 2 diabetes. At the same time, the number of women seeking HRT has surged dramatically following the FDA's 2025 removal of the black box warning from hormone therapy products. The overlap between these two groups is enormous: women in midlife dealing with both metabolic changes and hormonal decline.

Menopause and weight gain are deeply interconnected. As estrogen levels decline during perimenopause, the body shifts fat storage from the hips and thighs to the abdomen. Insulin sensitivity decreases. Metabolic rate slows. Many women gain 10 to 20 pounds during the menopause transition despite no changes in diet or exercise. It's one of the most frustrating symptoms, and it's driven countless women to GLP-1 medications in recent years.

But here's the disconnect: the major GLP-1 clinical trials — STEP, SURMOUNT, SUSTAIN — enrolled relatively few menopausal women, and none specifically analyzed results by menopause status or concurrent HRT use. So the data gap is real.

How menopause affects GLP-1 response

There's growing clinical evidence — mostly from endocrinologists and obesity medicine specialists reporting patterns in practice — that menopausal women may respond differently to GLP-1 medications compared to premenopausal women or men.

Several factors may be at play:

• Estrogen and insulin sensitivity: Estrogen plays a significant role in glucose metabolism and insulin sensitivity. When estrogen drops during menopause, insulin resistance increases. GLP-1 drugs work in part by improving insulin signaling, but they may be fighting an uphill battle without the metabolic support that estrogen provides.
• Estrogen and GLP-1 receptor expression: Animal studies have shown that estrogen influences GLP-1 receptor expression in the brain and pancreas. Lower estrogen levels may reduce the body's responsiveness to GLP-1 medications, which could partially explain why some menopausal women plateau faster on these drugs.
• Body composition changes: Menopausal fat redistribution toward visceral fat (the deep abdominal fat around organs) creates a different metabolic environment than subcutaneous fat. GLP-1 medications may interact with these fat stores differently.
• Appetite regulation: Estrogen is involved in regulating appetite through hypothalamic signaling. The loss of estrogen can amplify hunger signals that even GLP-1 drugs may not fully suppress.

What clinicians are seeing

Dr. Felice Gersh, an integrative OB/GYN and one of the few physicians studying this overlap, has noted that her menopausal patients on GLP-1 drugs often see better weight loss results when they're also on HRT. The hypothesis is straightforward: restoring estrogen helps normalize the metabolic dysfunction that menopause creates, allowing GLP-1 drugs to work more effectively.

This aligns with what we know about estrogen and metabolism from decades of research. The Kronos Early Estrogen Prevention Study (KEEPS) and the Early versus Late Intervention Trial with Estradiol (ELITE) both showed improvements in metabolic markers among women on HRT, including better insulin sensitivity and reduced visceral fat accumulation.

Do GLP-1 drugs interact with HRT?

This is the question everyone wants answered directly: is it safe to take Ozempic and estrogen at the same time?

The short answer: there are no known dangerous pharmacological interactions between GLP-1 receptor agonists and hormone replacement therapy. They work through entirely different mechanisms. GLP-1 drugs mimic the incretin hormone GLP-1, acting on receptors in the pancreas, brain, and gut. Estrogen and progesterone act through nuclear hormone receptors throughout the body. These pathways don't directly conflict.

However, there are some practical considerations:

• Absorption of oral medications: GLP-1 drugs slow gastric emptying — that's part of how they work. This can affect the absorption timing and possibly the bioavailability of oral medications, including oral estrogen or oral progesterone. If you take oral HRT, your provider may want to monitor your hormone levels more closely or consider switching to transdermal delivery (patches, gels, or creams) which bypass the GI tract entirely.
• Nausea management: Both GLP-1 medications and oral progesterone can cause nausea, especially when first starting. Taking both simultaneously might amplify this side effect. Timing doses separately — or using vaginal progesterone instead of oral — may help.
• Bone density: Rapid weight loss from GLP-1 drugs can accelerate bone loss, which is already a concern during menopause due to declining estrogen. HRT is actually protective for bone health, so women on both treatments may have a net benefit here — but it's worth monitoring with DEXA scans.
• Muscle mass: GLP-1 medications can cause significant muscle loss along with fat loss — in some studies, up to 40% of weight lost was lean mass. Estrogen helps preserve muscle mass and strength. Women on both treatments should prioritize resistance training and adequate protein intake.

The case for combining HRT with GLP-1 therapy

Here's where things get interesting. There's a growing argument among menopause and metabolic specialists that HRT and GLP-1 drugs may actually be complementary — that using them together may produce better outcomes than either alone for menopausal women dealing with weight gain.

The logic is sound:

• HRT addresses the root hormonal cause of menopausal metabolic dysfunction — declining estrogen — by restoring the hormone to physiologic levels.
• GLP-1 drugs address the downstream effects — appetite dysregulation, insulin resistance, and accumulated visceral fat — through a separate mechanism.
• Together, they tackle the problem from both directions. HRT restores the metabolic foundation while GLP-1 drugs provide additional appetite and glucose regulation.

A 2024 retrospective analysis from a large integrative medicine practice found that menopausal women who were on both HRT and GLP-1 medications lost an average of 18% of their body weight over 12 months, compared to 12% for those on GLP-1 alone. The combined group also reported better energy levels, mood, and sleep — likely because of the additional benefits of HRT beyond weight management.

What about tirzepatide (Mounjaro/Zepbound)?

Tirzepatide, the dual GIP/GLP-1 receptor agonist marketed as Mounjaro for diabetes and Zepbound for weight management, has shown even stronger weight loss results than semaglutide (Ozempic/Wegovy) in clinical trials. The same considerations apply regarding menopause and HRT interactions.

Notably, the SURMOUNT-2 trial enrolled adults with type 2 diabetes, and a subgroup analysis did look at results by sex. Women on tirzepatide lost significant weight, but the study didn't differentiate by menopause status. Future research is needed.

The muscle loss problem — and why it matters more for menopausal women

One of the most underappreciated risks of GLP-1 medications is the loss of lean muscle mass. For menopausal women, this deserves special attention.

Women already lose approximately 1% of muscle mass per year after age 40, a process called sarcopenia. Menopause accelerates this because estrogen supports muscle protein synthesis. When you add rapid weight loss from GLP-1 drugs on top of menopausal muscle loss, you can end up with significant functional decline — difficulty with stairs, reduced grip strength, increased fall risk.

This is where HRT may play a protective role. Estrogen therapy has been shown to slow sarcopenia and preserve lean mass during menopause. And testosterone, increasingly prescribed as part of comprehensive HRT, directly supports muscle maintenance and growth.

If you're on a GLP-1 drug, talk to your provider about:

• Resistance training at least 2 to 3 times per week
• Protein intake of at least 1 to 1.2 grams per kilogram of body weight daily
• Monitoring body composition, not just the number on the scale
• Whether HRT (including testosterone) might help preserve muscle during weight loss

What to ask your doctor

If you're on both GLP-1 medications and HRT — or considering starting either — here are the questions worth bringing to your next appointment:

• Should I switch from oral HRT to transdermal delivery to avoid absorption issues with my GLP-1 medication?
• Are you monitoring my bone density and muscle mass while I'm on GLP-1 drugs?
• Could starting HRT improve my response to GLP-1 medication?
• Should we check hormone levels more frequently while I'm on both treatments?
• What's our plan for maintaining weight loss if I stop the GLP-1 drug?

The bottom line

The intersection of GLP-1 drugs and menopause is one of the most important and underresearched areas in women's health right now. Millions of women are navigating both treatments with very little guidance tailored to their specific situation.

What we can say is this: there are no known dangerous interactions between GLP-1 medications and HRT. The two treatments work through different mechanisms, and there is growing evidence that they may be complementary. HRT addresses the underlying hormonal changes of menopause that contribute to weight gain, metabolic dysfunction, and muscle loss — while GLP-1 drugs provide additional support for appetite regulation and glucose control.

The most important thing you can do is find a provider who understands both menopause and metabolic health — someone who won't treat these as two separate problems being managed in two separate silos. Your hormones and your metabolism are deeply connected, and your care should reflect that.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider about your individual treatment plan, especially when combining medications.